Needham & Company LLC Reaffirms “Buy” Rating for Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics (NASDAQ:DFTX)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a research report issued on Monday, Benzinga reports. They presently have a $66.00 price target on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 69.71% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Stifel Nicolaus lifted their target price on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Finally, Oppenheimer reissued an “outperform” rating and issued a $70.00 price target on shares of Definium Therapeutics in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Definium Therapeutics has an average rating of “Buy” and a consensus price target of $63.00.

Definium Therapeutics Stock Performance

Definium Therapeutics stock opened at $38.89 on Monday. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market cap of $5.23 billion, a P/E ratio of -11.34 and a beta of 2.23. Definium Therapeutics has a 1-year low of $8.77 and a 1-year high of $49.70. The firm has a 50-day moving average of $43.01 and a 200-day moving average of $30.33.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Sell-side analysts expect that Definium Therapeutics will post -3.02 EPS for the current year.

Insider Buying and Selling at Definium Therapeutics

In other news, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 67,119 shares of company stock worth $2,887,496 over the last three months. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Sequoia Financial Advisors LLC bought a new position in shares of Definium Therapeutics in the second quarter worth approximately $812,000. WINTON GROUP Ltd purchased a new position in Definium Therapeutics in the 2nd quarter worth approximately $240,000. Engineers Gate Manager LP bought a new position in Definium Therapeutics in the 2nd quarter valued at approximately $481,000. Integrated Wealth Concepts LLC purchased a new stake in Definium Therapeutics during the 2nd quarter valued at $159,000. Finally, NewEdge Advisors LLC purchased a new stake in Definium Therapeutics during the 2nd quarter valued at $222,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.